Organization | Spaarne Gasthuis

Spaarne Gasthuis Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4

Founded: Haarlem Netherlands (2014)

Organization Overview

First Clinical Trial

2014

NCT00809913

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2023

Timeline

NOW

Now

Alternative names

Spaarne Gasthuis | Spaarne Hospital, Hoofddorp

Active Ingredients

Drugs in Phase 4 Trials (8)

Atosiban (tractocile) (1 trial)

ciprofloxacin (cipro) (1 trial)

clindamycin (cleocin) (1 trial)

dapagliflozin (farxiga) (1 trial)

diphtheria, tetanus and whole cell pertussis vaccine (Boostrix) (1 trial)

insulin human (humulin) (1 trial)

levofloxacin (levaquin) (1 trial)

rifampin (1 trial)

Drugs in Phase 3 Trials (1)

magnesium hydroxide (1 trial)

Drugs in Phase 2 Trials (1)

prednisolone (hydeltra) (1 trial)

Drugs in Other Trials (3)

dexamethasone (1 trial)

lidocaine (xylocaine) (1 trial)

methylprednisolone (medrol) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Communicable Diseases (Phase 4)

Fistula (Phase 2)

Hyperglycemia (Phase 4)

Infections (Phase 4)

Neointima (Phase 2)

Urinary Tract Infections (Phase 4)

Vascular Remodeling (Phase 2)

Whooping Cough (Phase 4)

Overview

Highest Phase: Phase 4
# of Trials: 8
# of Trial APIs: 13